150 related articles for article (PubMed ID: 25676387)
1. Development of a unified clinical trial database for Alzheimer's disease.
Neville J; Kopko S; Broadbent S; Avilés E; Stafford R; Solinsky CM; Bain LJ; Cisneroz M; Romero K; Stephenson D;
Alzheimers Dement; 2015 Oct; 11(10):1212-21. PubMed ID: 25676387
[TBL] [Abstract][Full Text] [Related]
2. Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database.
Ito K; Corrigan B; Romero K; Anziano R; Neville J; Stephenson D; Lalonde R
J Alzheimers Dis; 2013; 37(1):173-83. PubMed ID: 23803296
[TBL] [Abstract][Full Text] [Related]
3. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
[TBL] [Abstract][Full Text] [Related]
4. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
Truffinet P; Bordet R; Ménard J
Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
[TBL] [Abstract][Full Text] [Related]
5. Accelerating drug development for Alzheimer's disease through the use of data standards.
Neville J; Kopko S; Romero K; Corrigan B; Stafford B; LeRoy E; Broadbent S; Cisneroz M; Wilson E; Reiman E; Vanderstichele H; Arnerić SP; Stephenson D
Alzheimers Dement (N Y); 2017 Jun; 3(2):273-283. PubMed ID: 29067333
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
[TBL] [Abstract][Full Text] [Related]
8. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
9. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials.
Vellas B; Pesce A; Robert PH; Aisen PS; Ancoli-Israel S; Andrieu S; Cedarbaum J; Dubois B; Siemers E; Spire JP; Weiner MW; May TS
Alzheimers Dement; 2011 Jul; 7(4):e109-17. PubMed ID: 21784343
[TBL] [Abstract][Full Text] [Related]
10. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
AAPS J; 2010 Jun; 12(2):117-29. PubMed ID: 20077053
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
[TBL] [Abstract][Full Text] [Related]
12. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?
Gauthier S; Leuzy A; Rosa-Neto P
Neurodegener Dis; 2014; 13(2-3):197-9. PubMed ID: 23942173
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
Miller BW; Willett KC; Desilets AR
Ann Pharmacother; 2011 Nov; 45(11):1416-24. PubMed ID: 22028424
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
15. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil.
Jones RW; Schwam E; Wilkinson D; Waldemar G; Feldman HH; Zhang R; Albert K; Schindler R
Alzheimer Dis Assoc Disord; 2009; 23(4):357-64. PubMed ID: 19561444
[TBL] [Abstract][Full Text] [Related]
16. Scales as outcome measures for Alzheimer's disease.
Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
[TBL] [Abstract][Full Text] [Related]
17. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?
Snyder PJ; Kahle-Wrobleski K; Brannan S; Miller DS; Schindler RJ; DeSanti S; Ryan JM; Morrison G; Grundman M; Chandler J; Caselli RJ; Isaac M; Bain L; Carrillo MC
Alzheimers Dement; 2014 Nov; 10(6):853-60. PubMed ID: 25458309
[TBL] [Abstract][Full Text] [Related]
18. Task force on Alzheimer's disease trial methodology: recruitment and retention, data management and analysis. The use of imaging in recruitment: maintenance and methodological issues in Alzheimer's trials.
Suhy J
J Nutr Health Aging; 2012 Apr; 16(4):349-51. PubMed ID: 22499456
[TBL] [Abstract][Full Text] [Related]
19. Study design considerations: conducting global clinical trials in early Alzheimer's disease.
Schindler RJ
J Nutr Health Aging; 2010 Apr; 14(4):312-4. PubMed ID: 20306004
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of Alzheimer's disease: consequence for drug trials?
Devi G; Scheltens P
Alzheimers Res Ther; 2018 Dec; 10(1):122. PubMed ID: 30567585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
